Call for Papers for Journal of the National Cancer Institute (JNCI) Monograph: The Role of Integrative Oncology in Cancer Survivorship
Letters of Intent: October 1, 2013
Letters of Intent are being accepted for manuscripts focused on original research for a JNCI monograph dedicated to evaluating the science and impact of integrative oncology on cancer survivorship. This monograph is sponsored by the Society for Integrative Oncology, Consortium of Academic Health Centers for Integrative Medicine, the Abramson Cancer Center at University of Pennsylvania, Allina Health, Beth Israel Medical Center, University of Hawaii, and the University of Texas MD Anderson Cancer Center.
The peer-reviewed issue is scheduled for publication September 2014. It will include selected manuscripts on the science and evidence-based integration of complementary and integrative medicine (CIM) and lifestyle changes aimed at improving the physical, emotional, and spiritual aspects of quality of life and clinical outcomes for individuals affected by cancer.
Researchers from a diverse range of disciplines (including, but not limited to medicine, nursing, CIM, public health and health services, behavioral medicine, epidemiology, anthropology, and psychology) may contribute high quality empirical papers of original research in the following areas:
- Translational research to elucidate the mechanisms underlying integrative oncology
- Clinical trials to define the safety, efficacy, and effectiveness of integrative oncology
- Implementation and dissemination science to evaluate the integration of specific types of CIM or process of integration into cancer care
Letters of Intent must be received by October 1, 2013 to email@example.com, and must include a title, brief abstract, the type of research (e.g., clinical trial, observational, etc.), and list of authors.
Manuscripts deemed appropriate for this special issue must be received by January 15, 2014 via JNCI online submission portal – must include a cover letter indicating submission for this specific monograph and strictly conform to the author requirements and reference specifications of JNCI (see www.oxfordjournals.org).
Early detection combined with treatment advances have allowed many individuals with cancer to live longer. In the United States alone, 13.7 million individuals have a past diagnosis of cancer and are thus considered cancer survivors. As cancer affects individuals on physical, emotional, and spiritual levels, many cancer survivors use complementary and integrative
medicine (CIM) to regain a sense of control, address symptom burden, seek wellness, and improve outcomes. The convergence of the two exciting new fields, cancer survivorship and integrative oncology, creates enormous opportunities to ask important research questions and to develop innovative clinical models to promote the long term health and wellbeing for cancer survivors.
Despite the scientific promise and emerging empirical evidence, many questions remain unanswered:
What are the mechanisms underlying specific CIM practices (e.g., acupuncture, yoga, etc.) for symptom management?
How does stress reduction or dietary change affect biomarkers and clinical outcomes in cancer survivors?
What is the optimal way to integrate CIM practices in the growing field of survivorship clinical delivery?
How can CIM be delivered alongside conventional treatments to improve clinical outcomes?
What are the long term safety, efficacy, effectiveness, and cost-effectiveness of specific integrative approaches for improving symptom management in cancer survivors?
How do patients and providers make decisions to incorporate CAM approaches to manage pain and other symptoms common in cancer survivorship?
The JNCI Monograph, The Role of Integrative Oncology in Cancer Survivorship, will:
- Present and synthesize the state of science in integrative oncology.
- Identify scientific gaps and opportunities in integrative oncology.
- Discuss methodological challenges and propose solutions to enhance the quality of integrative oncology research.
- Provide evidence-based clinical guideline to inform integrative oncology delivery.
June J. Mao, MD, MSCE of University of Pennsylvania
Lorenzo Cohen, PhD of MD Anderson Cancer Center